Dianthus Therapeutics: The Next Giant in the Autoimmune Disease Market?

The increasing number of approved compounds for regulating the complement system presents companies with enormous market potential for treating rare immune diseases. Investments in this sector are particularly attractive, as new approaches to blocking specific proteins (such as C3 or C5) offer the potential for blockbuster drugs. Due to the essential role of the complement system in modern medicine, established players in this research area are often regarded as more crisis-resistant growth stocks in the biotech portfolio. Dianthus...